Skip to Main Content

Dermira has suffered a surprising and catastrophic failure of its experimental acne drug.

Across two separate but identically designed Phase 3 clinical trials, Dermira’s drug, a topical gel called DRM01, did not achieve any of its endpoints when compared to an inactive control gel, the company said Monday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED